Leadership Team

Scientific and Operational Team

×
Jaap Goudsmit, M.D., Ph.D.
Acting Chief Scientific Officer

Jaap Goudsmit, M.D., Ph.D., is a Dutch scientist, well-known for his research in the fields of HIV and influenza. During his career, Goudsmit published 560 scientific publications in peer-reviewed journals, nine of which appeared in Science, most recently in 2017, and six in Nature. Goudsmit was among the first in 1986 to discover that the amount of HIV in the blood predicted progression to clinical A.I.D.S. In 1989 Goudsmit discovered that HIV neutralizing antibodies target the V3 loop in the HIV envelope, a component closely linked with the virulence of HIV.

In 2002 Goudsmit joined Crucell, a biotechnology company in Leiden, Netherlands, as chief medical officer and executive vice-president of vaccine research and development. He and his team discovered adenovirus vector-based vaccines against Ebola and HIV, and a monoclonal antibody cocktail against rabies. Goudsmit discovered influenza hemagglutinin stem antibodies, which protect against A and B strains of Influenza, in 2006.

When Crucell was acquired by Johnson & Johnson in 2011, Goudsmit became head of the Crucell Vaccine Institute of Janssen, an institute focusing on influenza vaccine research. In 2015, he became global head of the Janssen Prevention Center, that focuses on the prevention of non-communicable diseases with a special emphasis on prognostic markers for age-related diseases. In 2017, Goudsmit retired from Johnson & Johnson.

Goudsmit was professor of virology from 1989-2001 at the University of Amsterdam, where he was one of the principal investigators of the Amsterdam Cohort Studies on HIV infection and AIDS among homosexual men and IV drug users. From 2001-2016, he was professor of vaccinology and immunoprophylaxis at the University of Amsterdam. In 2016, Goudsmit was appointed professor of epidemiology at the Harvard T.H. Chan School of Public Health. In 2016, Goudsmit also received an honorary degree from Vrije University and the Vrije University Medical Center (Netherlands) for his lifetime of scientific achievements in both academia and the biopharmaceutical industry.

Wayne Koff, Ph.D.
President & CEO

Wayne Koff, Ph.D., is the founding President and CEO of the Human Vaccines Project. Prior to joining the Project, Koff served as chief scientific officer and senior vice president of research and development at the International AIDS Vaccine Initiative (IAVI) in New York City (1999-2016), leading IAVI’s research and development program. At IAVI, his accomplishments included developing multiple HIV vaccines through clinical trials; establishing state-of-the-art laboratories in the U.S., Europe, India and Africa; conducting the first HIV vaccine trials in India, Kenya and Rwanda; establishing the Neutralizing Antibody Consortium, which identified new, broad and potent neutralizing antibodies against HIV that led to the discovery of novel targets for vaccine design; and establishing a clinical research network in Africa that has conducted seminal studies on HIV pathogenesis, incidence and acute infection.

Koff served as vice president of vaccine research and development at United Biomedical Inc. (UBI), where he was responsible for its vaccine R&D program. During his tenure at UBI (1992-1998), the company conducted the first AIDS vaccine clinical trials in the developing countries of the People’s Republic of China, Thailand, and Brazil.

He served as chief of the Vaccine Research and Development Branch, Division of AIDS, at the National Institute of Allergy and Infectious Diseases, where he led the team that established the pre-clinical and clinical AIDS vaccine development programs for the National Institutes of Health (1988-1992).

He received his B.A. from Washington University and his Ph.D. from Baylor College of Medicine. Koff has published more than 100 scientific papers and edited eight books on vaccine development. An internationally recognized viral immunologist in the field of AIDS vaccine research and development, he has been twice honored by the U.S. Department of Health and Human Services with the Special Act of Service Award for developing innovative strategies for accelerating global efforts in AIDS vaccine development.

Ted Schenkelberg, M.B.A., M.P.H.
Chief Operating Officer

Ted Schenkelberg, M.B.A., M.P.H., brings more than 15 years of experience applying business management principles to advance biomedical and global health priorities across the nonprofit and for-profit sectors. He is co-founder of the Human Vaccines Project where he currently serves as Chief Operating Officer.

Previously, Schenkelberg worked as a strategic consultant in the global health and biotech space, including work for a leading Indian health system and national initiatives on reproductive health and antibiotic resistance. He served for more than seven years as a Director at the International AIDS Vaccine Initiative (IAVI) where he played a key role in building a $50 million global vaccine design program.

Schenkelberg brings strong private sector experience having worked as a licensed health and technology analyst at Carnegie Capital, an investment firm with more than $1 billion under management and administration. He also has served on the board of directors for the African Services Committee in New York City, the largest U.S. organization supporting African immigrants and asylum seekers.

Schenkelberg has an M.P.H. in infectious disease from The Johns Hopkins Bloomberg School of Public Health, an M.B.A. from The University of Chicago Booth School of Business where he completed joint graduate work at the London School of Economics, and a B.A. in history (honors) from Grinnell College.

×
Sunny Bates
Development

Sunny Bates operates wherever executives, thinkers, artists, creators, innovators, entrepreneurs, educators, philanthropists connect and collide around the globe. Her genius is developing networks of extraordinary people and connecting their ideas in surprising ways toward concrete outcomes.

As an author, serial entrepreneur, mentor and advisor, her client roster has included some of the world’s most prominent organizations, from GE, TED and Credit Suisse to MTV, the National Academy of Sciences, Techstars and Kickstarter, of which she is a founding board member.

Neal N. Beaton, J.D.
Legal Counsel
Holland & Knight LLP

Neal Beaton, J.D., practices in the areas of life sciences, corporate and commercial transactions, and intellectual property. He is experienced in mergers and acquisitions, particularly on behalf of non-U.S. parties; venture capital and minority investments; pharmaceutical and intellectual property licensing, joint development and other technology agreements; joint ventures; distribution agreements; shareholder agreements; employment agreements; trademark and copyright protection; antitrust compliance; and corporate and visa planning.  Beaton has represented Japanese, European and U.S. pharmaceutical companies, biotech companies and not-for-profit entities dedicated to treating and eradicating diseases in worldwide, U.S. and Japanese pharmaceutical licenses as well as in research, collaboration, joint venture and equity investment agreements. Beaton has a law degree from Harvard Law School and an A.B. in government/international relations from Harvard College. He has bar admissions in the state of New York and various federal courts.

Bonnie Bender, M.P.H.
Senior Consultant

Bonnie Bender, M.P.H., is chief architect of the Human Vaccines Project’s Michelson Prize outreach campaign ensuring a high-quality applicant pool of young researchers for the prestigious annual prize. She also supports various aspects of the Project’s fundraising portfolio. Bender is an independent consultant working on a wide variety of global public health issues, including HIV/AIDS, HPV elimination and maternal immunization. She has more than 20 years of experience designing and managing health research and capacity-building programs in Africa, most recently as the Africa regional director for the International AIDS Vaccine Initiative based in Nairobi, Kenya. Bonnie holds a B.S. from Vassar College and an M.P.H .from Columbia University.

Linn Dorin. M.P.A.
Finance
Global Finance Strategies

Linn Dorin, M.P.A., is the founding principal of Global Finance Strategies and the COO/CFO of its parent organization Global Health Strategies, a global communications and advocacy firm with headquarters in New York City and offices in India, Brazil, China, Africa and the UK . A seasoned operations, people and finance executive, most recently she was the Chief Administrative Officer at Planned Parenthood Federation of America (PPFA), and before that, the CFO and SVP of Operations of the International AIDS Vaccine Initiative (IAVI). At PPFA, Linn recruited and mentored a team of operations executives to support the implementation of the new strategic plan, including a new CFO, General Counsel and Chief Human Resources Officer. During her 14 years at IAVI, Linn helped support the development of a $5 million-a-year nonprofit into a $100 million-a-year product-development partnership, with operations in Africa, India, Europe and elsewhere, and complex funding streams including U.S. Government and European Union funding. Prior to IAVI, Linn spent five years at Morgan Stanley as a vice president, and before that at Peat Marwick Mitchell & Company (now KPMG), working as a certified public accountant. Linn has a master’s degree in public administration from Columbia University.

Pat Fast, M.D., Ph.D.
Senior Clinical Consultant

Pat Fast, M.D., Ph.D., received her medical degree at Michigan State University, is board certified in pediatrics (University of Michigan), and also holds a Ph.D. in immunology from the University of California, Los Angeles. She has worked for more than 20 years on the clinical development of vaccines.

Fast joined the International AIDS Vaccine Initiative from the biotechnology company Aviron, where she oversaw studies of vaccines against influenza and cytomegalovirus. Before that, she led clinical research on HIV vaccines while serving as associate director for vaccines and prevention at the U.S. National Institute of Allergy and Infectious Diseases, Division of AIDS.

Fast also serves as the Chair for the Vaccine Advisory Committee of Aeras, currently serves on the UNAIDS/WHO Vaccine Advisory Committee and is Adjunct Clinical Associate Professor of Pediatric Infectious Diseases at Stanford University School of Medicine.

Lisa M.P. Munoz
Communications and Public Relations

Lisa M.P. Munoz leads communications and press relations at the Human Vaccines Project, working to share its cutting-edge science and innovative vision with scientific collaborators, donors, press, and the general public.

Munoz has 20 years of experience working with scientists around the world to help translate their complex work into digestible stories for broad audiences. Her expertise spans the biological sciences, the behavioral sciences, climate and energy, and the earth sciences. She is a former science journalist and was a press officer at the World Meteorological Organization in Geneva, Switzerland. Munoz has an engineering degree from Cornell University (cum laude) with a specialty in science writing. She is based in the Washington, D.C. area.

Nadia Rozendaal, M.Phil/M.B.A
Senior Advisor Europe

Nadia Rozendaal , M.Phil/M.B.A, has more than 20 years of experience in advocacy, fundraising, governmental affairs, communications, and global health. Before joining the Human Vaccines Project, Rozendaal was leading the European efforts of Aeras and helped to increase the European donor support for tuberculosis vaccine research and development. Rozendaal has also served as an independent consultant to a variety of global health organizations focusing on fundraising, business development and communications, having a broad network of governmental, private, and philanthropic influential individuals. She became a consultant after serving as a director for Policy Advocacy Europe for the International AIDS Vaccine Initiative (IAVI).

From 1994 to 2006, Rozendaal occupied different positions in Brussels, such as head of cabinet of the Austrian Social Democratic Delegation in the European Parliament; political adviser to the VP of the European Parliament, drafting legislation and policy frameworks in various parliamentary committees on economic affairs, competitiveness, trade, employment and foreign relations; a member of the External Speakers Team of the European Commission; a governmental affairs expert to various industry and non-profit organizations and trainer for European journalism and lobbying institutes.

During her time in Brussels, Rozendaal was also an election observer of the European Commission and the Organization for Security and Cooperation in Europe in conflict areas in several African and Asian countries. Rozendaal has studied in different European universities and holds a master’s degree in modern roman languages, a master’s degree in international politics/law/economics and a master’s degree in international business administration. Nadia is a German native speaker and fluent in English, French, Spanish, Italian, and Dutch.

Georges Thiry, Ph.D., PMP
Senior Scientific Consultant
Senergues Consult

Georges Thiry, Ph.D., PMP, is a vaccinologist, epidemiologist, and project management professional who has guided over 10 vaccine candidates to clinical testing. Thiry received his Ph.D. in science, microbiology, and genetics from the University of Liège in 1988, and has worked for nearly 30 years in translational R&D, project and portfolio management, and field operations. After completing his Ph.D., he worked at Solvay Animal Health on the development of veterinary vaccines. In 1995, Thiry became a senior project manager at GlaxoSmithKline, and in 2000 became director of project management at the International Aids Vaccine Institute (IAVI), where he managed a portfolio of international HIV vaccine R&D projects. As the director of portfolio management, ARVAC, for PATH in India, he supervised over 30 programs including the development of vaccines against rotavirus, influenza, RSV, pneumonia, polio, and enteric (ETEC, Shigella). In 2013, Thiry served as the deputy director general of the International Vaccine Institute in Soul, South Korea and Director of the Dengue Vaccine Initiative, conducting epidemiology in Vietnam, Thailand, and Colombia.

As senior clinical vice president, Head of Infectious Diseases at Hookipa Biotech in Vienna, Austria, Thiry led the translation from pre-clinical to first-in-human trial of a cytomegalovirus vaccine based on a non-replicating viral vector (LCMV). He is currently the CEO of Senergues Consult, a France-based consultancy providing services in vaccine R&D and project and portfolio management. Thiry is also a Certified Project Management Professional, having received accreditation in 2005 from the Project Management Institute.

Frans van den Boom, Ph.D. M.M.O.
Director Europe

Frans M. van den Boom, Ph.D., M.M.O., leads the Human Vaccines Project, Europe.  Van den Boom has more than 30 years of leadership and management experience in international, multilingual and cross-cultural organizations, ranging from startups to mature organizations. He held previous positions with Qatar Foundation Research & Development as executive director for policy, planning and evaluation; the Dutch Top Sector Life Sciences and Health as executive director and secretary general; the National Committee for International Cooperation and Sustainable Development as president and CEO; and the International AIDS Vaccine Initiative as vice president of Country and Regional Programs. Van den Boom has unique experience working with state and non-state actors in high-, middle-, and low-income countries, working at the interfaces of political outreach, public policy development, planning, resource mobilization, and communication. He has long-term experience in research, analysis, and evaluation; project and program management; and leading grant-making organizations, and resource mobilization efforts.

Van den Boom holds an M.M.O. degree from the TIAS School for Business and Society, University of Tilburg (Netherlands). He attained an M.S. degree from Radboud University (Netherlands) and taught social sciences as a faculty member. After completing his Ph.D. at University of Amsterdam (Netherlands), he became a member of the faculty of medicine.

Sabrina Welsh, M.P.H.
Director of Programs and Operations

Sabrina Welsh, M.P.H., brings over 10 years of international clinical trial and program management experience to her role at the Human Vaccines Project. As Director of Programs and Operations, Sabrina oversees the clinical operations within the Project’s network, applying a project management-driven approach to help ensure efficient and high-quality operations.

Before joining the Human Vaccines Project, Welsh worked as the senior clinical program manager for the International AIDS Vaccine Initiative (IAVI), where she led early clinical development project teams for vaccines and monoclonal antibodies for the prevention of HIV and other emerging infectious diseases. Welsh also helped develop the Epidemiology for Vaccine Advancement, Capacity and Science (EpiVACS) program at IAVI, where her work focused on acute HIV infection and access to health care in marginalized key populations. Sabrina received an M.P.H. from the New York University College of Global Public Health and a B.S. with distinction in research from Cornell University.

Stacey Wooden, Ph.D., M.P.H.
Principal Scientist

Stacey Wooden, Ph.D., M.P.H., is a cross-trained scientist with expertise in human immunology, vaccine development, collaborative research, and global public health. She received her Ph.D. in human immunology from the Johns Hopkins School of Medicine and the Bloomberg School of Public Health at Hopkins, studying the role of the non-classical MHC during the immune response to Gram-negative enteric bacteria.  She conducted a postdoctoral fellowship at the University of Maryland Center for Vaccine Development, where she studied cell-mediated immunity and correlates of protection in early phase trials of live oral attenuated vaccines for S. flexneri and S. typhi.

Wooden has served as a Peace Corps volunteer, Fulbright Scholar, and UNICEF consultant in southern Africa. She has worked as the chief scientific officer for an HIV cure collaboratory based at the University of North Carolina Chapel Hill, and as a senior scientific review officer managing the peer review of vaccine development proposals submitted to the U.S. Department of Defense. She is also the founder and director of Global Health Alliance, an organization dedicated to creating and managing international alliances to address the health needs of underserved populations around the world.

Subscribe to our Newsletter